Corporate Statement

Mallinckrodt Pharmaceuticals is a multibillion dollar specialty pharmaceutical company focused on our mission: Managing Complexity. Improving Lives. We provide medicines to address unmet patient needs, stemming from 150 years of using our unique strengths, experience and expertise to help improve people’s lives. Discover how our rich history of innovation and patient-centered solutions has helped influence our vision for the future.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Overview

News Releases

22 Feb '22
DUBLIN , Feb. 22, 2022 /PRNewswire/ -- Mallinckrodt plc  (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Company's New Drug Application (NDA) seeking approval for the
03 Feb '22
DUBLIN , Feb. 3, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ) ("Mallinckrodt" or the "Company") today announced that its Plan of Reorganization (the "Plan") has been confirmed by the U.S. Bankruptcy Court for the District of Delaware , paving the way for the Company to begin the next
16 Dec '21
-- Company pursuing additional indication for FDA-approved product as part of clinical development program -- DUBLIN , Dec. 16, 2021 /PRNewswire/ -- Mallinckrodt plc  (OTCMKTS:MNKKQ), a global biopharmaceutical company, today announced enrollment of the first patient in StrataSOMA , a Phase 1/2a

Recent Events

Featured Reports

go back to the top of the page